Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.48 |
| ▸ | RARG | P13631 | 7/20 | 0.48 |
| ▸ | RARA | P10276 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.48 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929560 | 0.92 | RARB (0.44) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL7513943 | 0.91 | RARG (0.48) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL1361020 | 0.89 | MEN1 (0.58) | RARBRARGRARAMEN1KMT2A | |
| Acetic Acid SCHEMBL7926656 | 0.88 | RARB (0.48) | RARBRARGRARAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7929420 | 0.88 | MEN1 (0.57) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL8457127 | 0.87 | RARB (0.48) | RARBRARGRARAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8458532 | 0.86 | RARB (0.47) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL7926557 | 0.86 | RARB (0.45) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL2919467 | 0.85 | IKBKB (0.52) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL29462745 | 0.85 | IKBKB (0.52) | RARBRARGRARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255543-B1 | USE OF RETINOID-TYPE COMPOUNDS AS ANTIBACTERIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | GALDERMA RES & DEV (FR) | 2010-09-01 | — | — | EP | claimed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | claimed |
| EP-1143920-B1 | OIL-IN-WATER EMULSION COMPRISING A MICRONISED BIOLOGICALLY ACTIVE AGENT AND AN APPROPRIATE EMULSIFIER SYSTEM | GALDERMA RES & DEV (FR) | 2003-08-27 | — | — | EP | claimed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | claimed |
| EP-0892633-B1 | USE OF INHIBITORS OF THE ACTIVITY OF RETINOIC ACID FOR TREATING SENSITIVE SKIN AND/OR ACUTE DAMAGE INDUCED BY UV RADIATION | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-03-05 | — | — | EP | claimed |
| US-20020035161-A1 | O/W emulsions comprising micronized biologically active agents | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2002-03-21 | — | — | US | claimed |
| EP-0854711-B1 | gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR | GALDERMA RECH DERMATOLOGIQUE (FR) | 2002-01-23 | — | — | EP | claimed |
| US-6248749-B1 | TOPICALLY APPLYING RETINOID ANTAGONIST TO SENSITIVE SKIN TO TREAT ALLERGIES/SUNBURN | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2001-06-19 | — | — | US | claimed |
| US-6063797-A | γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor | C.I.R.D. GALDERMA (FR) | 2000-05-16 | — | — | US | claimed |
| US-8969544-B2 | Combined use of PRAME inhibitors and HDAC inhibitors | BERNARDS RENé (NL) | 2015-03-03 | — | — | US | disclosed |
| EP-1711210-B1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2013-12-11 | — | — | EP | disclosed |
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | BERNARDS RENE (NL) | 2013-05-16 | — | — | US | disclosed |
| EP-2392677-A2 | Combined use of prame inhibitors and hdac inhibitors | TopoTarget UK Limited (GB) | 2011-12-07 | — | — | EP | disclosed |
| US-7928081-B2 | biodrugs contains siRNA or vector encoding siRNA, including a retinoid as antitumor agents, anticarcinogenic agents | Bernards, Rene (NL) | 2011-04-19 | — | — | US | disclosed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | disclosed |
| US-20020035161-A1 | O/W emulsions comprising micronized biologically active agents | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6248749-B1 | TOPICALLY APPLYING RETINOID ANTAGONIST TO SENSITIVE SKIN TO TREAT ALLERGIES/SUNBURN | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2001-06-19 | — | — | US | disclosed |
| US-6225328-B1 | FOR THERAPY OF DISORDERS OR AILMENTS RELATED TO AN OVERREGULATION OF RETINOIC ACID RECEPTORS AND/OR TO HYPERVIAMINOSIS A | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2001-05-01 | — | — | US | disclosed |
| US-6063797-A | γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor | C.I.R.D. GALDERMA (FR) | 2000-05-16 | — | — | US | disclosed |
| EP-0740937-A2 | Use of retinoids for the manufacture of a pharmaceutical or cosmetic composition | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | HDAC5, HDAC8, HDAC11 | RARB 14/4885RARG 24/4885RARA 29/4885 |
| US-20020035161-A1 | O/W emulsions comprising micronized biologically active agents | NOTUM, SOAT2, SOAT1 | RARB 335/4885RARG 204/4885RARA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.